Juan M Jiménez Vacas
@juanjimenezvacas.bsky.social
Postdoctoral Researcher at The Institute of Cancer Research. ESE Young Endocrinologists and Scientists (EYES) Co-Chair.
Excited to share our new study from @asharpmedonc.bsky.social lab at @icr.ac.uk 🔬✨
We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social
🔗 bit.ly/4oHSvNx
We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social
🔗 bit.ly/4oHSvNx
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Targeting anti-apoptotic BCL2 family proteins is an attractive therapeutic strategy
to drive prostate cancer (PCa) cell death. Here, we show that MCL1 is highly expressed
in castration-resistant PCa (...
www.cell.com
November 14, 2025 at 8:43 PM
Excited to share our new study from @asharpmedonc.bsky.social lab at @icr.ac.uk 🔬✨
We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social
🔗 bit.ly/4oHSvNx
We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.
So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social
🔗 bit.ly/4oHSvNx
It’s my first #Movember! 🥸
As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙
Join me on this Mo journey! 👨🏻🔬
movember.com/m/15464015?m...
As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙
Join me on this Mo journey! 👨🏻🔬
movember.com/m/15464015?m...
Juan M Jiménez Vacas's Mo Space
Juan M's Motivation: I’m a prostate cancer researcher at The Institute of Cancer Research in London. Like many others, I’ve been personally affected by this disease — both my grandad and my dad had pr...
movember.com
November 5, 2025 at 6:09 PM
It’s my first #Movember! 🥸
As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙
Join me on this Mo journey! 👨🏻🔬
movember.com/m/15464015?m...
As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙
Join me on this Mo journey! 👨🏻🔬
movember.com/m/15464015?m...
The importance of fundamental research! 🧪🧫👩🔬👨🔬
Funders must recognise that great discoveries often come from studies that seeks to advance knowledge for its own sake
go.nature.com/3X5lbUg
go.nature.com/3X5lbUg
From MRI to Ozempic: breakthroughs that show why fundamental research must be protected
Nature - In these financially straitened times, funders must recognize that great discoveries often arise from work that was looking for something completely different.
go.nature.com
November 2, 2025 at 10:13 AM
The importance of fundamental research! 🧪🧫👩🔬👨🔬
Reposted by Juan M Jiménez Vacas
Our fantastic @prostateukprofs.bsky.social career development fellow @juanjimenezvacas.bsky.social takes a closer look at a potential new treatment approach for #ProstateCancer that has stopped responding to existing therapies ⬇️.
🚨 Delighted to share our latest paper, from
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
October 16, 2025 at 10:42 AM
Our fantastic @prostateukprofs.bsky.social career development fellow @juanjimenezvacas.bsky.social takes a closer look at a potential new treatment approach for #ProstateCancer that has stopped responding to existing therapies ⬇️.
This was my last meeting with the @ese-eyes.bsky.social News editorial committee, the newsletter of the early career group of the @esendocrinology.bsky.social
Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!
Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!
November 1, 2025 at 2:34 PM
This was my last meeting with the @ese-eyes.bsky.social News editorial committee, the newsletter of the early career group of the @esendocrinology.bsky.social
Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!
Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!
🚨 Delighted to share our latest paper, from
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
October 15, 2025 at 1:48 PM
🚨 Delighted to share our latest paper, from
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4
Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social
@prostateukprofs.bsky.social
@prostateukprofs.bsky.social
Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer?
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...
October 14, 2025 at 4:20 PM
Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social
@prostateukprofs.bsky.social
@prostateukprofs.bsky.social
Reposted by Juan M Jiménez Vacas
Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer?
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...
October 14, 2025 at 4:02 PM
Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer?
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...
A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.
Grab a ☕ and read: doi.org/10.1038/s414...